# Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

> **NCT00327600** · PHASE1,PHASE2 · COMPLETED · sponsor: **AmpliMed Corporation** · enrollment: 68 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** imexon
- **DRUG:** DTIC

## Key facts

- **NCT ID:** NCT00327600
- **Lead sponsor:** AmpliMed Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2007-01
- **Final completion:** 2007-12
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2010-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00327600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00327600, "Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00327600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*